Measuring and valuing outcomes

Hampson, G., Mott, D. Devlin, N. and Shah, K.

Consulting Report
January 2019

Whether or not society values curative therapies more highly (or less highly) than the sum of the iterative improvements that might come from conventional therapy has been highlighted as an important area for research. The aim of this research was thus to explore society’s preferences across curative and non-curative therapies and large and small health gains, via a discrete choice experiment.

Cole, A. and Towse, A.

Consulting Report
December 2018

The proliferation of health data in our ever more digitalised world of health care creates opportunities for better research around – and delivery of – pharmaceutical innovation. However, these opportunities may be constrained around the legal barriers to the use of health data for these purposes, which are poorly understood, particularly in relation to the new General Data Protection Regulation (GDPR).

A new OHE-authored paper on the relationship between age and health-related quality of life has been published in Quality of Life Research.

NICE has issued a new position statement regarding the use of the EQ-5D-5L value set in evidence submitted to its HTA process.

OHE has published a response to the critique of the EQ-5D-5L value set for England study.

The Office of Health Economics

Briefing
November 2018

This is OHE’s report to the Charity Commission for England and Wales for the year 2017, OHE’s first since becoming a registered charity in December 2016. It demonstrates some of the ways in which OHE has met its charitable objects: namely, to advance the education of the public in general/health care payers/policy makers on the subject of health economics and health care policy.

OHE will be hosting two lunchtime seminars in October – one on the 22nd with Steven Pearson, ICER, and another on the 31st with Janel Hanmer, University of Pittsburgh.

OHE contributed to the organisation and scientific content of the recent EuroQol Plenary Meeting in Lisbon, Portugal.

When should progression-free survival be used as a surrogate for overall survival in oncology? Uneven reporting of results – different definitions and methods of analysis, lack of rigour in applying methodology – make progress difficult.

OHE’s Koonal Shah and Nancy Devlin are co-authors on two new papers focusing on the valuation of the EQ-5D-5L in Ireland.

Pages

Subscribe to RSS - Measuring and valuing outcomes